The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report
  ()
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

  ()
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.

Expert Rates Pharma Co. An Immediate Buy

Contributed Opinion
  ()
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.

FDA OKs Biopharma to Trial New Cell Therapy

Research Report
  ()
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.

Delay in New Drug Filing Now Could Yield Benefits Later

Research Report
  ()
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.

ACC Recommends Approved Drug for Lowering LDL

Research Report
  ()
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula

  ()
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.

First Data Due by Year End 2022 From Study of New HAE Drug

Research Report
  ()
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.

New Schizophrenia Drug Has Chance of Getting FDA Approved

Research Report
  ()
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report.

Hedge Fund Doubles Position in Biotech Co.

  ()
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.

Expert Sees Even More 'Good News' From Pharma Co.

Contributed Opinion
  ()
Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.

Biotech Co. Has Multiple Shots on Goal

Research Report
  ()
This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report.

Price Target on Cancer Drug Co. Boosted

Research Report
  ()
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report.

Healthcare Co. Brings Treatment to Canadian Alcohol Addiction Market

  ()
One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one.

Biotech Co. To Receive 66% Funding From UK Gov.

Contributed Opinion
  ()
Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders.

Life Sciences Co. Gets Big Order for Livestock Feed Additive

Research Report
  ()
This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report.

Firm Sees Boost in Sales of Health Chewable for Dogs

Research Report
  ()
Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report.

News Update

Healthcare Co. Enters US Alcohol Addiction Treatment Market

  ()
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics.

Co. Provides Ground-Floor Opportunity in Precision Oncology

Research Report
  ()
Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma.

Biotech Co. Nearing Milestones for HBV Drugs

Research Report
  ()
Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50.

Showing Results: 26 to 50 of 145 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts